Where such associations have been investigated in the clinical setting, melanoma BRAF mutation status has not been found to be predictive of patient response to anti-PD1/PD-L1 treatment (55–57), while PTEN loss in melanoma may predict inferior patient response to treatment with PD1/PD-L1 antagonists (57, 58). This evidence concerns the gene PTEN and melanoma.